These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1812379)

  • 1. Development of an in vivo 19F magnetic resonance method for measuring oxygen deficiency in tumors.
    Raleigh JA; Franko AJ; Kelly DA; Trimble LA; Allen PS
    Magn Reson Med; 1991 Dec; 22(2):451-66. PubMed ID: 1812379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a fluorinated 2-nitroimidazole binding to hypoxic cells in tumor-bearing rats by 19F magnetic resonance spectroscopy and immunohistochemistry.
    Kwock L; Gill M; McMurry HL; Beckman W; Raleigh JA; Joseph AP
    Radiat Res; 1992 Jan; 129(1):71-8. PubMed ID: 1728059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
    Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
    Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
    Aboagye EO; Kelson AB; Tracy M; Workman P
    Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
    Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
    Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.
    Lee CP; Payne GS; Oregioni A; Ruddle R; Tan S; Raynaud FI; Eaton D; Campbell MJ; Cross K; Halbert G; Tracy M; McNamara J; Seddon B; Leach MO; Workman P; Judson I
    Br J Cancer; 2009 Dec; 101(11):1860-8. PubMed ID: 19935799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV; Ji M; Bloomer WD
    Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors.
    Salmon HW; Siemann DW
    Radiother Oncol; 2004 Dec; 73(3):359-66. PubMed ID: 15588883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554.
    Aboagye EO; Maxwell RJ; Horsman MR; Lewis AD; Workman P; Tracy M; Griffiths JR
    Br J Cancer; 1998; 77(1):65-70. PubMed ID: 9459147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.
    Seddon BM; Maxwell RJ; Honess DJ; Grimshaw R; Raynaud F; Tozer GM; Workman P
    Clin Cancer Res; 2002 Jul; 8(7):2323-35. PubMed ID: 12114437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV; Pouremad R; Rao MK; Ji M; Bloomer WD
    In Vivo; 2001; 15(5):365-71. PubMed ID: 11695231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors.
    Procissi D; Claus F; Burgman P; Koziorowski J; Chapman JD; Thakur SB; Matei C; Ling CC; Koutcher JA
    Clin Cancer Res; 2007 Jun; 13(12):3738-47. PubMed ID: 17575240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy.
    el-Tahtawy A; Wolf W
    Cancer Res; 1991 Nov; 51(21):5806-12. PubMed ID: 1933851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35 T.
    Raleigh JA; Franko AJ; Treiber EO; Lunt JA; Allen PS
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1243-5. PubMed ID: 3744946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo.
    McSheehy PM; Robinson SP; Ojugo AS; Aboagye EO; Cannell MB; Leach MO; Judson IR; Griffiths JR
    Cancer Res; 1998 Mar; 58(6):1185-94. PubMed ID: 9515804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
    Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
    J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo measurement of the hypoxia marker EF5 in Shionogi tumours using (19)F magnetic resonance spectroscopy.
    Hoff MN; Yapp DT; Yung AC; Oliver TS; Kozlowski P
    Int J Radiat Biol; 2008 Mar; 84(3):237-42. PubMed ID: 18300024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.
    Seddon BM; Payne GS; Simmons L; Ruddle R; Grimshaw R; Tan S; Turner A; Raynaud F; Halbert G; Leach MO; Judson I; Workman P
    Clin Cancer Res; 2003 Nov; 9(14):5101-12. PubMed ID: 14613987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.
    Maxwell RJ; Workman P; Griffiths JR
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):925-9. PubMed ID: 2703398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI.
    Gonzales C; Yoshihara HA; Dilek N; Leignadier J; Irving M; Mieville P; Helm L; Michielin O; Schwitter J
    PLoS One; 2016; 11(10):e0164557. PubMed ID: 27736925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.